The impact of race on outcomes of autologous transplantation in patients with multiple myeloma

American Journal of Hematology

Volumn 83, Issue 5, 2008, Pages 355-358

  Verma, Pramvir S ^a   Howard, Robin S ^a   Weiss, Brendan M ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CREATININE; HEMOGLOBIN;

ADULT; AFRICAN AMERICAN; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTOTRANSPLANTATION; CANCER RELAPSE; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; AFRICAN AMERICANS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH SERVICES ACCESSIBILITY; HOSPITALS, MILITARY; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROPORTIONAL HAZARDS MODELS; SOCIOECONOMIC FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 42949083135     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21139     Document Type: Article

References (25)

1. Blattner WA. Epidemiology of multiple myeloma and related plasma cell disorders: An analytic review. In: Potter M, editor. Progress in Myeloma. New York: Elsevier North Holland; 1980. pp 1-65.
2. Age-Adjusted Total U.S. Mortality for Myeloma by Race from 1969-2003. Available at http://seer.cancer.gov [Accessed February 14, 2007].
3. Brown LM, Pottern LM, Silverman DT, et al. Multiple myeloma among Blacks and Whites in the United States: Role of cigarettes and alcoholic beverages. Cancer Causes Control 1997;8:610-614.
4. Lewis DR, Pottern LM, Brown LM, et al. Multiple myeloma among blacks and whites in the Unites States: The role of chronic antigenic stimulation. Cancer Causes Control 1994;5:529-539.
5. Jacobson RJ, Shulman G.Plasma cell myeloma and Waldenstrom's macroglobulinemia in black and white South Africans. In: Potter M, editor. Progress in Myeloma. New York: Elsevier North Holland; 1980. pp 81-91.
6. Savage D, Lindenbaum J, Van Ryzin J, et al. Race, poverty, and survival in multiple myeloma. Cancer 1984;54:3085-3094.
7. Woods LM, Rachet B, Coleman MP. Origins of socio-economic inequalities in cancer survival: A review. Ann Oncol 2006;17:5-19.
8. Benjamin M, Reddy S, Brawley OW, et al. Myeloma and race: A review of the literature. Cancer Metastasis Rev 2003;22:87-93.
9. Modiano MR, Villar-Werstler P, Crowley J, Salmon SE. Evaluation of race as a prognostic factor in multiple myeloma: An ancillary of southwest oncology group study 8229. J Clin Oncol 1996;14:974-977.
10. Levy V, Katsahian S, Fermand JP, et al. A meta-analysis on data from 575 patients with multiple myeloma randomly assigned to either high-dose therapy or conventional therapy. Medicine (Baltimore) 2005;84:250-260.
11. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348: 1875-1883.
12. Saraf S, Chen Y-H, Dobogai N, et al. Prolonged responses after autologous stem cell transplantation in African-American patients with multiple myeloma. Bone Marrow Transplant 2006;37:1099-1102.
13. Tienhaara A, Pulkki K, Mattila K, et al. Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with multiple myeloma at diagnosis. Br J Haematol 1994;86:391-393.
14. Child J, Morgan G, Davies F, et al. High dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-1883.
15. Attal M, Harousseau J, Facon T, et al. Single versus double autologous transplantation for multiple myeloma. N Engl J Med 2003;349:2495-2502.
16. Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 2006;107: 904-906.
17. Zhan F, Barlogie B, Shaughnessy JD, et al. A gene expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007;109:1692-1700.
18. Pineda-Roman M, Bolejack V, Arzoumanian V, et al. Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. Br J Haematol 2007;136:393-399.
19. Rajkumar SV. MGUS and smoldering multiple myeloma: Update on pathogenesis, natural history, and management. Hematology (Am Soc Hematol Educ Program) 2005:340-345.
20. Blade J, Rosinol L. Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance. Curr Treatment Options Oncol 2003;7: 237-245.
21. Wojcik BE, Spinks MK, Optenberg SA. Breast carcinoma survival analysis for African-American and White women in an equal-access health care system. Cancer 1998;82:1310-1318.
22. Carey LA, Perous CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-2502.
23. Mohla S, Sampson CC, Khan T, et al. Estrogen and progesterone receptors in breast cancer in black Americans: Correlation of receptor data with tumor differentiation. Cancer 1982;50:552-559.
24. Greip PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-3420.
25. Blade J, Samson D, Reece D, et al. on behalf of Myeloma Subcommittee of the EBMT (European Group for Blood and Marrow Transplant). Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115-1123.